Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ault

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Obstetrics and Gynecology|January 9, 2015
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidanceWarner K Huh, Kevin A Ault, David Chelmow, et al.
Vaccine|August 3, 2013
Research on vaccines during pregnancy: reference values for vital signs and laboratory assessmentsJeanne S Sheffield, Flor M Munoz, Richard H Beigi, et al.
Vaccine|April 10, 2019
Development and acceptability of a video-based vaccine promotion tutorial for obstetric care providersA T Chamberlain, R J Limaye, S T O'Leary, et al.
BMC Public Health|November 21, 2022
MomsTalkShots, tailored educational app, improves vaccine attitudes: a randomized controlled trialMatthew Z Dudley, Saad B Omer, Sean T O'Leary, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Obstetrics and Gynecology|January 9, 2015
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidanceWarner K Huh, Kevin A Ault, David Chelmow, et al.
Vaccine|August 3, 2013
Research on vaccines during pregnancy: reference values for vital signs and laboratory assessmentsJeanne S Sheffield, Flor M Munoz, Richard H Beigi, et al.
Vaccine|April 10, 2019
Development and acceptability of a video-based vaccine promotion tutorial for obstetric care providersA T Chamberlain, R J Limaye, S T O'Leary, et al.
BMC Public Health|November 21, 2022
MomsTalkShots, tailored educational app, improves vaccine attitudes: a randomized controlled trialMatthew Z Dudley, Saad B Omer, Sean T O'Leary, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Pageof 15